IP Library › Granted Patent US 12,344,901
Granted Patent B2
US 12,344,901 · App. 17/883,414 · Granted Jul 1, 2025

Automated methods of detecting cell free DNA

Inventors: Jared Robert Maguire (San Francisco, CA); Clement S. Chu (San Francisco, CA); Imran Saeedul Haque (San Francisco, CA); Eric Andrew Evans (San Bruno, CA); Noah Welker (Half Moon Bay, CA)
Assignee: Myriad Women's Health, Inc.
C12Q1/6886C12Q1/6818C12Q1/6874G01N35/0099C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,901
App. No.
17/883,414
Granted
Jul 1, 2025
Kind
B2
Abstract

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

Claims (25)

1. An automated method of detecting a DNA fragment, comprising:

(i) receiving, via an application module configured to receive commands from at least one of a user computing device or a script server, a workflow process corresponding to a result to be obtained based on operations on a sample selected from whole blood, plasma, or serum from a subject with a history of cancer;

(ii) obtaining, via an automation system configured to interface with laboratory equipment, based on the workflow process, a container with the sample from an origin location;

(iii) performing, by the automated system,

(a) extracting cell free DNA (cfDNA) from the sample;

(b) enriching, from the extracted cfDNA, a DNA fraction of fragments comprising one or more of a plurality of tumor-specific somatic mutations that are specific to the subject and that were determined prior to obtaining the sample by sequencing genomic DNA from a solid tumor sample previously obtained from the subject and genomic DNA from a non-tumor sample previously obtained from the subject;

(c) sequencing the enriched fraction of fragments; and

(d) detecting a presence or absence of a DNA fragment comprising any one of the plurality of tumor-specific somatic mutations in the enriched DNA fraction of fragments; and

(iv) generating a report comprising the result of the detection of the presence or absence of the DNA fragment.

2. The method of claim 1 , wherein the cfDNA is extracted from the sample using a liquid handling apparatus configured for extraction of components of samples.

3. The method of claim 1 , further comprising providing, by the application module, the report to a user device.

4. The method of claim 1 , wherein the result is presence or absence of a molecule in the sample.

5. The method of claim 1 , wherein the automation system is configured to interface with the laboratory equipment using one or more robotics units.

6. The method of claim 1 , wherein the enriching comprises hybrid capture-based enrichment, PCR-target enrichment, or on-sequencer enrichment.

7. The method of claim 1 , wherein the method comprises a detection sensitivity of 20 to 50 ctDNA fragments comprising one or more of the plurality of somatic mutations in fluid sample per a total background of 500,000 cfDNA fragments.

8. The method of claim 1 , wherein hybrid capture-based enrichment is used to enrich the DNA fraction of fragments comprising one or more of the plurality of tumor-specific somatic mutations.

9. The method of claim 8 , wherein hybrid capture-based enrichment comprises:

(i) contacting the extracted cfDNA with a plurality of oligonucleotides that each comprise a nucleic acid sequence that is capable of hybridizing to one of the plurality of tumor-specific somatic mutations; and

(ii) selectively enriching cfDNA fragments that hybridize to the plurality of oligonucleotides.

10. The method of claim 9 , wherein the plurality of oligonucleotides is capable of detecting at least 10 different tumor-specific somatic mutations.

11. The method of claim 1 , wherein sequencing comprises whole genome sequencing.

12. The method of claim 1 , wherein sequencing comprises targeted sequencing.

13. The method of claim 1 , further comprising determining a fraction of the cfDNA fragments that are circulating tumor DNA (ctDNA) fragments.

14. The method of claim 1 , wherein the mutations in the plurality of tumor-specific somatic mutations comprise one or more mutations selected from SNPs, insertions, deletions, and translocations.

15. The method of claim 1 , further comprising repeating the method on a second sample obtained from the subject at a later date.

Assignments (5)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032) Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
PATENT SECURITY AGREEMENT Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2023
From: MAGUIRE, JARED ROBERT; CHU, CLEMENT; HAQUE, IMRAN SAEEDUL; EVANS, ERIC ANDREW; WELKER, NOAH
To: COUNSYL, INC.
Reel/Frame 064109/0373 →
CHANGE OF NAME Recorded Jun 29, 2023
From: COUNSYL, INC.
To: MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 064163/0011 →
Continuity (6)
Continuation 17678829 · Feb 23, 2022
Continuation 17383273 · Jul 22, 2021
Continuation 16784761 · Feb 7, 2020
Continuation 15465553 · Mar 21, 2017
Provisional Application 62311899 · Mar 22, 2016
Related Publication 20230295716A1 · Sep 21, 2023
References Cited (77)
US 6306597B1 · Macevicz · 2001 [cited by applicant]
US 7115400B1 · Adessi et al. · 2006 [cited by applicant]
US 7232656B2 · Balasubramanian et al. · 2007 [cited by applicant]
US 7323305B2 · Leamon et al. · 2008 [cited by applicant]
US 10597717B2 · Maguire et al. · 2020 [cited by applicant]
US 11932910B2 · Maguire et al. · 2024 [cited by applicant]
US 12024749B2 · Maguire et al. · 2024 [cited by applicant]
US 20080160580A1 · Adessi et al. · 2008 [cited by applicant]
US 20080286795A1 · Kawashima et al. · 2008 [cited by applicant]
US 20120208705A1 · Steemers et al. · 2012 [cited by applicant]
US 20130225452A1 · Pollack et al. · 2013 [cited by applicant]
US 20130261019A1 · Lin et al. · 2013 [cited by applicant]
US 20130296183A1 · Eggan · 2013 [cited by examiner]
US 20140342354A1 · Evans et al. · 2014 [cited by applicant]
US 20150080266A1 · Volkmuth et al. · 2015 [cited by applicant]
US 20150301058A1 · Schettini et al. · 2015 [cited by applicant]
US 20150376700A1 · Schnall-Levin et al. · 2015 [cited by applicant]
US 20160053301A1 · Raymond et al. · 2016 [cited by applicant]
WO WO2011103236A2 · 2011 [cited by applicant]
WO WO2013112923A1 · 2013 [cited by applicant]
WO WO2014015084A2 · 2014 [cited by applicant]
WO WO2014151117A1 · 2014 [cited by applicant]
WO WO2016040901A1 · 2016 [cited by applicant]
Decision to Grant in EP 17771023.3 dated Dec. 16, 2021, 2 pages. [cited by applicant]
European Communication issued in corresponding EP Application No. 17771023.3, dated Jun. 12, 2020, 4 pages. [cited by applicant]
European Communication issued in corresponding EP Application No. 17771023.3, dated Oct. 30, 2020, 3 pages. [cited by applicant]
European Communication under Rule 71(e)EPC in EP Application No. 17771023.3, dated Jul. 30, 2021, 93 pages. [cited by applicant]
Extended European Search Report and Written Opinion issued in corresponding EP Application No. 17771023.3, dated Oct. 25, 2019 (6 pages). [cited by applicant]
Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” Sci Transl Med, 4(136):136ra68, 13 pages (May 30, 2012). [cited by applicant]
Leary et al., “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” Sci Transl Med, 2(20):20ra14, 8 pages (Feb. 24, 2010). [cited by applicant]
Ley et al., “CDNA Sequencing of a Cytogenetically Normal Acute Myeloid Leukaemia Genome,” Nature, 456(7218):66-72 (Nov. 6, 2008). [cited by applicant]
Summons to Attend Oral Proceedings (including Preliminary Decision) in 17771023.3 dated Oct. 2, 2023, 19 pages. [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology, 1990, pp. 403-410, vol. 215, 1990 Academic Press Limited. [cited by applicant]
Botezatu et al., “Genetic Analysis of DNA Excreted in Urine: A New Approach for Detecting Specific Genomic DNA Sequences from Cells Dying in an Organism”, Clinical Chemistry, vol. 46, No. 8, May 22, 2000, pp. 1078-1084. [cited by applicant]
Branton et al., “The potential and challenges of nanopore sequencing”, Nat. Biotechnol., vol. 26, 2008, pp. 1146-1153. [cited by applicant]
Browning et al., “Haplotype phasing: Existing methods and new developments”, Nat. Rev. Genet., vol. 12, Apr. 1, 2012, pp. 703-714. [cited by applicant]
Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing”, Clinical Chemistry, vol. 59… [cited by applicant]
Chen et al., “Microsatellite alterations in plasma DNA of small cell lung cancer patients”, Nature Medicine, vol. 2, No. 2, Sep. 1996, pp. 1033-1035. [cited by applicant]
Duncavage et al., “Hybrid Capture and Next-Generation Sequencing Identify Viral Integration Sites from Formalin-Fixed, Paraffin-Embedded Tissue”, The Journal of Molecular Diagnostics, May 3, 2011, vol. 13, No. 3, pp. 32… [cited by applicant]
Fan et al., “Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood”, PNAS, vol. 105, No. 42, Oct. 21, 2008, pp. 16266-16271. [cited by applicant]
Fierer et al., “The influence of sex, handedness, and washing on the diversity of hand surface bacteria”, Proc. Nat'l Adad. Sci., vol. 105, Nov. 18, 2008, pp. 17,994-17,999. [cited by applicant]
Gnirke et al., “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing”, Nature Biotechnology, vol. 27, No. 2, Feb. 2009, pp. 182-189. [cited by applicant]
Gudmundsson et al., “Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility”, Nat Genet., vol. 41, No. 10, Oct. 2009, pp. 1122-1126. [cited by applicant]
Hamady et al., “Error-correcting barcoded primers allow hundreds of samples to by pyrosequenced in multiplex”, Nature Methods, vol. 5, No. 3, 2008, pp. 235-237. [cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proceedings of the National Academy of Sciences USA, vol. 89, Nov. 1992, pp. 10915-10919. [cited by applicant]
Higgins et al., “CLUSTAL: a package for performing multiple sequence alignment on a microcomputer,” Dec. 15, 1988, Gene, vol. 73, No. 1, pp. 237-244. [cited by applicant]
Hopp et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification,” Bio/Technology, Oct. 1988, vol. 6, pp. 1204-1210. [cited by applicant]
Horhota et al., “Glycerol nucleoside triphosphates: synthesis and polymerase substrate activities”, Organic Letters, Sep. 8, 2006, vol. 8, No. 23, pp. 5345-5347. [cited by applicant]
International Search Report and Written Opinion issued in corresponding International Application No. PCT/US2017/023482, dated Jul. 27, 2017 (13 pages). [cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci., vol. 90, Jun. 1993, pp. 5873-5877. [cited by applicant]
Koide et al., “Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women,” Prenatal Diagnosis, vol. 25, No. 7, Jul. 2005, pp. 604-607. [cited by applicant]
Koren et al., One chromosome, one contig: Complete microbial genomes from long-read sequencing and assembly, Curr. Opin. Microbiol. vol. 23, Dec. 1, 2014, pp. 110-120. [cited by applicant]
Krishnan et al., Barcodes for DNA Sequencing with guaranteed error correction and capability, Electronics Letter, vol. 47, 2011, pp. 236-237. [cited by applicant]
Langmead et al., “Ultrafast and memory-efficient alignment of short DNA sequences to the human genome”, Genome Biology, vol. 10, Issue 3, Mar. 4, 2009 (10 pages). [cited by applicant]
Lefrancois et al., Efficient yeast ChiP-Seq using multiplex short-read DNA sequencing, BMC Genomics, vol. 10, 2009, pp. 1-18. [cited by applicant]
Li et al., “The Sequence Alignment/Map format and SAMtools”, Bioinformatics, vol. 25, No. 16, 2009, pp. 2078-2079. [cited by applicant]
Lo et al., “Presence of fetal DNA in maternal plasma and serum”, The Lancet, vol. 350, Aug. 16, 1997, pp. 485-487. [cited by applicant]
Lutz-Freyermuth et al., “Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of … [cited by applicant]
Martin et al., “GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Currents”, Science, vol. 255, No. 5041, Jan. 10, 1992, pp. 192-194. [cited by applicant]
Mertes et al., “Targeted enrichment of genomic DNA regions for next-generation sequencing”, Briefings in Functional Genomics, 2011, vol. 10, No. 6, pp. 374-386. [cited by applicant]
Metzker, Michael, “Sequencing technologies—the next generation”, Nature Reviews, vol. 11, Jan. 2010, pp. 31-46. [cited by applicant]
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Mol. Biol., vol. 48, Mar. 28, 1970, pp. 443-453. [cited by applicant]
Skinner et al., “Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins”, The Journal of Biological Chemistry, vol. 266, No. 22, Aug.… [cited by applicant]
Su et al., “Human Urine Contains Small, 150 to 250 Nucleotide-Sized, Soluble DNA Derived from the Circulation and May Be Useful in the Detection of Colorectal Cancer”, Journal of Molecular Diagnostics, vol. 6, No. 2, Ma… [cited by applicant]
Turner et al., “Massively parallel exon capture and library-free resequencing across 16 genomes”, Nat. Methods, 6:315-316, 2009. [cited by applicant]
Voelkerding et al., “Next-Generation Sequencing: From Basic Research to Diagnostics”, Clinical Chemistry, vol. 55, No. 4, 2009, pp. 641-659. [cited by applicant]
Dawson et al., “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer”, The New England Journal of Medicine, 2013, vol. 368, No. 13, pp. 1199-1209 and Supplemental Appendix. [cited by applicant]
Diehl et al., “Circulating mutant DNA to assess tumor dynamics”, Nat Med., 2008, vol. 14, No. 9, pp. 985-990. [cited by applicant]
Garcia-Murillas et al., “Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer”, Sci Transl Med., 2015, vol. 7, No. 302, 13 pages. [cited by applicant]
Lipson et al., “Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade”, J Immunother Cancer. 2014, 7 pages. [cited by applicant]
Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nat. Med., 2014, vol. 20, No. 5 (45 pages). [cited by applicant]
Wagle et al., “High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing”, Cancer Discovery, 2012, vol. 2, No. 1, pp. 82-93. [cited by applicant]
Woo et al., “Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma”, PLoS One, 2014, vol. 9, No. 12, 15 pages. [cited by applicant]
Butler et al., “Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease,” PLOS One, 10(8):e0136407, pp. 1-14 (Aug. 28, 2015). [cited by applicant]
Pereira et al., “Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers,” PLoS One 10(12):e0145754, p. 1-13 and Figure S1 and Table S1, 15 pages total (2… [cited by applicant]
Takai et al., “Clinical Utility of Circulating Tumor DNA for Molecular Assessment in Pancreatic Cancer,” Nature Scientific Reports, 5:18425, p. 1-10 and Supplementary Information, 43 pages total (2015). [cited by applicant]
Thermo Fisher Scientific. “Ion AmpliSeq™ Designer provides full flexibility to sequence genes of your choice” Application Note. Ionu AmpliSeq™ Custom Panels. 4 pages, available via URL: <assets.thermofisher.com/TFS-Asse… [cited by applicant]